Table 3. Overview of univariate and... | American Society of Hematology

Table 3.

Overview of univariate and multivariate results of intergroup comparisons

	UVA P	MVA P	Supplemental material
GVL vs noGVL			Table 5A
Figure 2B CD8⁺ 1/D	.0051	.0309	Table 5B
Figure 3B Δ no. of clones top 25%	.0172	.0326	Table 5C
Figure 3B Δ no. of clones top 50%	.0200	.0380	Table 5D
Figure 3B Δ no. of clones top 75%	.0179	.0480	Table 5E
Figure 3B Δ no. of clones whole repertoire	.0287	.5600	Table 5F
Figure 4B Δ CD8⁺TRB repertoire occupation by top 20 clones	.0051	.0069	Table 5G
Figure 4B Δ CD8⁺TRB repertoire occupation by top 21-50 clones	.1700	.6273	Table 5H
Figure 4B Δ CD8⁺TRB repertoire occupation by top 51-N clones	.0248	.0186	Table 5I
Figure 5B Δ CD8⁺TRB repertoire occupation by top 20 overlapping clones	.0442	.0306	Table 5J
Figure 5B Δ CD8⁺TRB repertoire occupation by top 21-N overlapping clones	.8400	.6098	Table 5K
Figure 5B Δ CD8⁺TRB repertoire occupation by all overlapping clones	.0018	.0121	Table 5L
Figure 5F Δ overlapping DLI CD8⁺ clones	.0128	.0024	Table 5M
Figure 5G Δ new DLI CD8⁺ clones	.7780	.0415	Table 5N
No relapse vs relapse			Table 6A-B
Figure 6B CD8⁺ 1/D	.0142	.0066	Table 6C
Figure 6D Δ no. of clones top 25%	.0107	.0034	Table 6D
Figure 6D Δ no. of clones top 50%	.0242	.0133	Table 6E
Figure 6D Δ no. of clones top 75%	.4363	.1815	Table 6F
Figure 6D Δ no. of clones whole repertoire	.8633	.4480	Table 6G
Figure 6F Δ CD8⁺TRB repertoire occupation by top 20 clones	.0244	.0073	Table 6H
Figure 6F Δ CD8⁺TRB repertoire occupation by top 21-50 clones	1.0000	.4050	Table 6I
Figure 6F Δ CD8⁺TRB repertoire occupation by top 51-N clones	.2581	.1220	Table 6J
Figure 6H Δ CD8⁺TRB repertoire occupation by top 20 overlapping clones	.0503	.0308	Table 6K
Figure 6H Δ CD8⁺TRB repertoire occupation by top 21-N overlapping clones	.5613	.7643	Table 6L
Figure 6H Δ CD8⁺TRB repertoire occupation by all overlapping clones	.0770	.0660	Table 6M
CD8⁺ expansion vs no expansion			Table 7A-B, D
Figure 7A CIR	.0040	.0080	Table 7C
Figure 7B Relapse-free survival	.0150	.0210	Table 7E

	UVA P	MVA P	Supplemental material
GVL vs noGVL			Table 5A
Figure 2B CD8⁺ 1/D	.0051	.0309	Table 5B
Figure 3B Δ no. of clones top 25%	.0172	.0326	Table 5C
Figure 3B Δ no. of clones top 50%	.0200	.0380	Table 5D
Figure 3B Δ no. of clones top 75%	.0179	.0480	Table 5E
Figure 3B Δ no. of clones whole repertoire	.0287	.5600	Table 5F
Figure 4B Δ CD8⁺TRB repertoire occupation by top 20 clones	.0051	.0069	Table 5G
Figure 4B Δ CD8⁺TRB repertoire occupation by top 21-50 clones	.1700	.6273	Table 5H
Figure 4B Δ CD8⁺TRB repertoire occupation by top 51-N clones	.0248	.0186	Table 5I
Figure 5B Δ CD8⁺TRB repertoire occupation by top 20 overlapping clones	.0442	.0306	Table 5J
Figure 5B Δ CD8⁺TRB repertoire occupation by top 21-N overlapping clones	.8400	.6098	Table 5K
Figure 5B Δ CD8⁺TRB repertoire occupation by all overlapping clones	.0018	.0121	Table 5L
Figure 5F Δ overlapping DLI CD8⁺ clones	.0128	.0024	Table 5M
Figure 5G Δ new DLI CD8⁺ clones	.7780	.0415	Table 5N
No relapse vs relapse			Table 6A-B
Figure 6B CD8⁺ 1/D	.0142	.0066	Table 6C
Figure 6D Δ no. of clones top 25%	.0107	.0034	Table 6D
Figure 6D Δ no. of clones top 50%	.0242	.0133	Table 6E
Figure 6D Δ no. of clones top 75%	.4363	.1815	Table 6F
Figure 6D Δ no. of clones whole repertoire	.8633	.4480	Table 6G
Figure 6F Δ CD8⁺TRB repertoire occupation by top 20 clones	.0244	.0073	Table 6H
Figure 6F Δ CD8⁺TRB repertoire occupation by top 21-50 clones	1.0000	.4050	Table 6I
Figure 6F Δ CD8⁺TRB repertoire occupation by top 51-N clones	.2581	.1220	Table 6J
Figure 6H Δ CD8⁺TRB repertoire occupation by top 20 overlapping clones	.0503	.0308	Table 6K
Figure 6H Δ CD8⁺TRB repertoire occupation by top 21-N overlapping clones	.5613	.7643	Table 6L
Figure 6H Δ CD8⁺TRB repertoire occupation by all overlapping clones	.0770	.0660	Table 6M
CD8⁺ expansion vs no expansion			Table 7A-B, D
Figure 7A CIR	.0040	.0080	Table 7C
Figure 7B Relapse-free survival	.0150	.0210	Table 7E

Given are the UVA and MVA results for the intergroup comparisons of Figures 2-7. UVA for Figures 2-6 were done with Mann-Whitney test (two-tailed, exact). UVA for Figure 7A was done with Gray’s test and for Figure 7B with univariate Cox regression analysis. MVA for Figures 2-6 employed analysis of variance testing, either with all variables (categorized to 2 levels, when applicable) for the GVL vs noGVL comparison or using only variables significantly correlating with dependent variables at P < .25 for the no relapse vs relapse comparison. MVA of Figure 7 used multivariate Cox regression models. Variables found to be significant with P < .25 in respective UVA were used in MVA. Backward elimination procedure was used to reduce the number of variables until remaining variables were fitting a model at P < .05. Details of MVA are shown in the supplemental material.

View Large

This Feature Is Available To Subscribers Only